:XF-73
{{use dmy dates|date=February 2016}}
{{Chembox
| ImageFile = XF 73.svg
| ImageSize = 250px
| ImageAlt =
| IUPACName =
| OtherNames =
|Section1={{Chembox Identifiers
| CASNo = 718638-68-7
| CASNo_Ref = {{cascite|correct|}}
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 1912L54M2V
| PubChem = 9918582
| ChemSpiderID = 8094227
| InChI = 1/C44H50N6O2.2ClH/c1-49(2,3)25-7-27-51-37-17-9-31(10-18-37)43-39-21-13-33(45-39)29-35-15-23-41(47-35)44(42-24-16-36(48-42)30-34-14-22-40(43)46-34)32-11-19-38(20-12-32)52-28-8-26-50(4,5)6;;/h9-24,29-30,45-46H,7-8,25-28H2,1-6H3;2*1H/q+2;;/p-2/b33-29-,34-30-,35-29-,36-30-,43-39-,43-40-,44-41-,44-42-;;
| InChIKey = BXHQXSXRVAELBC-NDLTUMITBE
| StdInChI = 1S/C44H50N6O2.2ClH/c1-49(2,3)25-7-27-51-37-17-9-31(10-18-37)43-39-21-13-33(45-39)29-35-15-23-41(47-35)44(42-24-16-36(48-42)30-34-14-22-40(43)46-34)32-11-19-38(20-12-32)52-28-8-26-50(4,5)6;;/h9-24,29-30,45-46H,7-8,25-28H2,1-6H3;2*1H/q+2;;/p-2/b33-29-,34-30-,35-29-,36-30-,43-39-,43-40-,44-41-,44-42-;;
| StdInChIKey = BXHQXSXRVAELBC-XRFOENPRSA-L
| SMILES = C[N+](C)(C)CCCOC(C=C1)=CC=C1/C(C2=CC=C(/C=C3C=CC(/C(C4=CC=C(OCCC[N+](C)(C)C)C=C4)=C(N/5)/C=CC5=C\6)=N/3)N2)=C7N=C6C=C/7.[Cl-].[Cl-]}}
|Section2={{Chembox Properties
| C=44 | H=50 | N=6 | O=2 | Cl=2
| Appearance =
| Density =
| MeltingPt =
| BoilingPt =
| Solubility = }}
|Section3={{Chembox Hazards
| MainHazards =
| FlashPt =
| AutoignitionPt = }}
}}
XF-73 (Exeporfinium chloride) is an experimental drug candidate. It is an anti-microbial that works via weakening bacteria cell walls. It is a potential treatment for methicillin-resistant Staphylococcus aureus (MRSA) and possibly Clostridioides difficile. It is being developed by Destiny Pharma Ltd.{{cite web |url=http://www.destinypharma.com/xf73.shtml |publisher=Destiny Pharma |title=XF-73|date=29 July 2016 }} (Shows molecular structure.){{cite journal |last1=Miller |first1=K. |last2=Ooi |first2=N. |last3=Hobbs |first3=J. K. |last4=Rhys-Williams |first4=W. |last5=Love |first5=W. G. |last6=Hayter |first6=I. |last7=Katila |first7=M. |last8=Chopra |first8=I. |url=http://www.blackwellpublishing.com/eccmid18/abstract.asp?id=68457 |publisher=European Society of Clinical Microbiology and Infectious Diseases |title=XF-73, a novel anti-staphylococcal antimicrobial with very rapid bactericidal activity |date=19 April 2008}}{{cite news |author=Mary Dejevsky |url=https://www.independent.co.uk/news/science/scientists-on-brink-of-cure-for-superbug-830345.html |archive-url=https://ghostarchive.org/archive/20220507/https://www.independent.co.uk/news/science/scientists-on-brink-of-cure-for-superbug-830345.html |archive-date=7 May 2022 |url-access=subscription |url-status=live |title=Scientists 'on brink of cure' for superbug |newspaper=The Independent |date=18 May 2008}}{{cbignore}}
Structurally, it is a dicationic porphyrin.{{cite web |url=http://www.destinypharma.com/xfseries.shtml |publisher=Destiny Pharma |title=XF series|date=29 July 2016 }}
It has completed a phase I clinical trial for nasal decolonisation of MRSA—being tested against 5 bacterial strains. It seems unlikely to cause MRSA to develop resistance to it.{{cite news |author=Neka Sehgal |url=http://www.themoneytimes.com/featured/20100920/promising-new-drug-xf73-kills-superbugs-within-5-minutes-id-10129029.html |title=Promising new drug XF-73 kills superbugs within 5 minutes |date=20 September 2010 |archive-url=https://web.archive.org/web/20110721204201/http://www.themoneytimes.com/featured/20100920/promising-new-drug-xf73-kills-superbugs-within-5-minutes-id-10129029.html |archive-date=21 July 2011 |url-status=live}}{{cite news |author=Tom Chivers |date=18 May 2008 |url=https://www.telegraph.co.uk/news/uknews/1981019/MRSA-UK-scientists-%27close-to-a-treatment%27.html |archive-url=https://archive.today/20130421084826/http://www.telegraph.co.uk/news/uknews/1981019/MRSA-UK-scientists-%27close-to-a-treatment%27.html |url-status=dead |archive-date=21 April 2013 |title=MRSA: UK scientists 'close to a treatment |newspaper=The Daily Telegraph}}
In 2014, a phase 1 clinical trial for nasal administration was run.[https://clinicaltrials.gov/ct2/show/NCT02282605 Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects]
{{As of |2022|6}}, another phase 1 clinical trial (for nasal administration) completed recruiting in 2016 but no results have been posted.[https://clinicaltrials.gov/ct2/show/NCT01592214 Study of the Safety and Local Tolerability of Intranasal Gel Formulations of XF-73]